CINECA IRIS Institutional Research Information System

BRUNETTO, MAURIZIA ROSSANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.260
EU - Europa 5.931
AS - Asia 3.350
AF - Africa 150
SA - Sud America 34
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 5
Totale 30.746
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.675
IT - Italia 1.661
CN - Cina 1.652
SE - Svezia 1.167
BG - Bulgaria 1.032
SG - Singapore 707
CA - Canada 582
DE - Germania 448
UA - Ucraina 421
VN - Vietnam 397
TR - Turchia 290
GB - Regno Unito 279
FI - Finlandia 213
CH - Svizzera 183
FR - Francia 172
HK - Hong Kong 131
RU - Federazione Russa 118
AT - Austria 90
IN - India 70
CI - Costa d'Avorio 67
BE - Belgio 35
NL - Olanda 25
BR - Brasile 23
BJ - Benin 22
JP - Giappone 20
SN - Senegal 20
RO - Romania 17
CZ - Repubblica Ceca 13
NG - Nigeria 13
AU - Australia 12
IR - Iran 12
PK - Pakistan 12
GR - Grecia 11
KR - Corea 10
ES - Italia 9
EG - Egitto 8
TW - Taiwan 8
ET - Etiopia 7
ID - Indonesia 7
IQ - Iraq 7
TH - Thailandia 7
HU - Ungheria 6
CL - Cile 5
EU - Europa 5
IE - Irlanda 5
MY - Malesia 5
PL - Polonia 5
DK - Danimarca 4
MR - Mauritania 4
NZ - Nuova Zelanda 4
PE - Perù 4
PH - Filippine 4
MD - Moldavia 3
MX - Messico 3
PT - Portogallo 3
SA - Arabia Saudita 3
AR - Argentina 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
IL - Israele 2
KE - Kenya 2
NP - Nepal 2
RS - Serbia 2
TN - Tunisia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BN - Brunei Darussalam 1
DZ - Algeria 1
HR - Croazia 1
LK - Sri Lanka 1
LT - Lituania 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NO - Norvegia 1
SI - Slovenia 1
UG - Uganda 1
Totale 30.746
Salva come PNG Salva come JPEG
Città #
Fairfield 3.080
Woodbridge 3.041
Ann Arbor 1.791
Houston 1.744
Ashburn 1.449
Seattle 1.235
Sofia 1.032
Cambridge 1.007
Wilmington 965
Chandler 935
New York 683
Milan 642
Beijing 570
Jacksonville 564
Ottawa 557
Boardman 493
Singapore 445
Princeton 439
Lawrence 429
Medford 353
Des Moines 328
Nanjing 272
Bern 175
Istanbul 170
San Diego 167
Dearborn 160
Dong Ket 151
Frankfurt am Main 130
Hong Kong 122
Nanchang 122
Izmir 103
Jüchen 99
Vienna 88
Serra 87
Ogden 80
Kunming 78
Abidjan 66
Shenyang 65
Changsha 63
Florence 59
Hefei 56
London 54
Pisa 54
Rome 50
Hebei 49
Redwood City 48
Chicago 44
Washington 42
Jiaxing 41
Boulder 40
Tianjin 40
Norwalk 39
Shanghai 33
Pune 31
Brussels 29
Jinan 26
Lancaster 24
Los Angeles 24
Fuzhou 23
Cotonou 22
Santa Clara 22
Dallas 21
Dakar 20
Falls Church 20
Bremen 19
Guangzhou 18
Verona 16
Orange 15
Toronto 15
Quanzhou 14
Lucca 13
Auburn Hills 12
Hangzhou 12
Wuhan 12
San Francisco 11
Xian 11
Boydton 10
Kilburn 10
Marseille 10
Paris 10
Council Bluffs 9
Chengdu 8
Prague 8
Redmond 8
Taipei 8
Changchun 7
Düsseldorf 7
Hyderabad 7
Detroit 6
Indiana 6
Lagos 6
Phoenix 6
Simi Valley 6
São Paulo 6
Zhengzhou 6
Bologna 5
Bucharest 5
Budapest 5
Cairo 5
Edinburgh 5
Totale 25.228
Salva come PNG Salva come JPEG
Nome #
Active HBV replication in HBsAg carriers with chronic Delta infection 186
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 183
Development of a liver model using PAM scaffolds in static and dynamic conditions 172
Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen 164
Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound 158
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study 158
Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen 156
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment 152
Sequence variation in hepatitis C viral isolates 145
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B 140
A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers 139
A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease 136
Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease? 136
Liver stiffness, a non-invasive marker of liver disease in the HBV carrier 136
Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D 135
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases 134
Multicenter evaluation of the elecsys hepatitis B surface antigen quantitative assay 134
Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview 132
'e' antigen defective hepatitis B virus and course of chronic infection 131
High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders 130
Hepatitis delta virus, a model of liver cell pathology 129
REPLICATING AND VIRION SECRETING HEPATITIS B MUTANT VIRUS UNABLE TO PRODUCE PRES2 PROTEIN 128
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations 128
Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by in situ hybridization 127
T-lymphocyte response to hepatitis C virus in different clinical courses of infection 127
Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects 126
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers 126
A multiphase model of th dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alfa2a, lamivudine and combination therapy 125
Potential applications of extracorporeal photopheresis in liver transplantation 125
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 125
Software and expert system for the management of chronic hepatitis B 124
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 124
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells 123
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 123
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study 122
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 122
Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values 121
Hepatitis B virus surface antigen levels: a guide to sustained response to Peginterferon alfa-2a in HBeAg-negative chronic hepatitis B 121
Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C 121
Precore mutant hepatitis B virus and outcome of chronic infection and hepatitis in hepatitis B e antigen-positive children 120
A dynamic analysis of IgM anti-HCV helps to distinguish hepatitis C from acute rejection in liver transplant patients 120
Personalized Therapy in chronic viral hepatitis 120
Variants of hepatitis B virus 119
Quantitative analysis of wild-type and HBeAg minus hepatitis B viruses by a sequence-dependent primer extension assay 119
Hepatitis B virus unable to secrete e antigen 118
Possible immunopathogenesis for fibrosing cholestatic hepatitis 118
Hepatitis C virus infection in type II essential mixed cryoglobulinemias 118
Problems in diagnosing viral hepatitis 118
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths 117
Severe liver injury possibly due to verapamil 116
Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B 115
IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease? 115
Diagnosis and monitoring of hepatitis virus infection in liver transplant patients 115
Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey 114
Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging 114
Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin 113
The natural history of chronic delta hepatitis 113
Validation and comparison of different PCR-based methods for detection of Hepatitis B virus precore region mutants 113
Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences 112
Comparable function of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors 111
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic Hepatitis B 109
Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. 109
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection 109
Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy 109
A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2a (40kd) (PEGASYS (R)), lamivudine, or PEGASYS (R) plus lamivudine combin 108
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C 107
Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies 106
Introduction to 'Hepatitis B virus heterogeneity--a means to personalized care' 106
Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen 106
Role of hepatitis delta virus infection in hepatocellular carcinoma 104
Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer 104
Laparoscopic robot-assisted distal splenorenal shunt 104
The role of quantitative hepatitis B surface antigen revisited 104
Patterns of natural killer cell function activation in response to interferon in chronic HBsAG positive hepatitis: relationship with the state of viral infection and with the early clinical response 103
Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study 103
Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. 103
The hepatitis C virus carrier with "persistently" normal serum transaminases: a misleading clinical issue 103
IN VITRO LIVER MODEL USING MICROFABRICATED SCAFFOLDS IN A MODULAR BIOREACTOR 103
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy 103
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 103
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 102
Ruolo degli acidi nucleici e marcatori immunologici nella diagnosi e gestione del portatore cronico di virus epatici maggiori (B, C e D) 102
Asymptomatic hypermylasemia and hyperlipasemia associated with aripiprazole 102
Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection 101
Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study 101
New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases 101
Diagnostic markers of chronic hepatitis B infection and disease” 100
Characterization of hepatitis delta antigen gene of a highly pathogenic strain of hepatitis delta virus 99
Uridine diphosphate glucoronosyl transferases, candidate antigens of liver-kidney microsomal antibodies in hepatitis delta virus-infected patients 99
Hepatitis C virus infection and liver disease: peculiar epidemiological and clinicopathological features 98
Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. 97
Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? 97
Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study 97
Rapidly progressive HBsAg hepatitis in Italy: a syndrome of Delta hepatitis virus superinfection 96
Does HBeAg minus HBV modify the course of HDV superinfection? 96
Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis 96
null 96
Recurrence of hepatitis B after liver transplantation is associated with intrahepatic HBcAg and serum IgM anti-HBc 96
Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research 96
null 95
Totale 11.835
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.657
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.657
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.736 0 0 0 0 764 778 769 638 757 431 486 113
2020/20212.917 275 157 204 159 194 123 202 236 356 234 220 557
2021/20224.370 130 272 73 269 776 676 171 200 244 212 161 1.186
2022/20233.220 613 317 204 247 340 455 34 230 528 24 180 48
2023/20243.385 429 312 368 170 489 821 64 75 79 41 84 453
2024/20251.210 37 503 120 523 27 0 0 0 0 0 0 0
Totale 31.298